Quarterly ResultMay 15, 2026, 07:02 AM
Indaptus Q1 Net Loss $2.5M; Strategic Review Underway
AI Summary
Indaptus Therapeutics reported a net loss of $2.5 million, or $0.23 per share, for the first quarter ended March 31, 2026, an improvement from a $4.5 million net loss in the prior year. The company saw reduced R&D and G&A expenses. However, cash and cash equivalents significantly declined to $1.5 million, and the company stated it needs to raise additional capital. Indaptus is also undergoing an executive management transition and a strategic review of its development programs and resource allocation.
Key Highlights
- Net loss for Q1 2026 was $2.5 million, compared to $4.5 million in Q1 2025.
- Loss per share for Q1 2026 was $0.23, compared to $9.11 in Q1 2025.
- Research and development expenses decreased by $2.3 million to $0.5 million in Q1 2026.
- General and administrative expenses decreased by $0.1 million to $1.7 million in Q1 2026.
- Cash and cash equivalents were $1.5 million as of March 31, 2026, down from $8.5 million on December 31, 2025.
- Net cash used in operating activities increased to $7.0 million in Q1 2026 from $5.0 million in Q1 2025.
- All outstanding Series AA and Series AAA Preferred Stock were converted into common stock during Q1 2026.
- Company is evaluating its Decoy platform and reassessing development priorities and resource allocation.
Price Impact
More from INDP